Nuveen
INBX icon

Nuveen’s Inhibrx INBX Stock Holding History

Nuveen’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
18,658
+1,481
+9% +$148K ﹤0.01% 2636
2026
Q1 		$1.15M Buy
17,177
+87
+0.5% +$6.45K ﹤0.01% 2519
2025
Q4 		$1.35M Sell
17,090
-494
-3% -$33.7K ﹤0.01% 2465
2025
Q3 		$592K Sell
17,584
-3,630
-17% -$89.4K ﹤0.01% 2838
2025
Q2 		$303K Sell
21,214
-3,807
-15% -$49.2K ﹤0.01% 3052
2025
Q1 		$350K Hold
25,021
– – ﹤0.01% 3000
2024
Q4 		$385K Sell
25,021
-15,850
-39% -$241K ﹤0.01% 3070
2024
Q3 		$640K Buy
40,871
+20,166
+97% +$283K ﹤0.01% 2928
2024
Q2 		$293K Buy
+20,705
New +$323K ﹤0.01% 3156

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's INBX Position: Q2 2026 in Review

Nuveen increased its Inhibrx (INBX) stake by 8.6% in Q2 2026, buying an estimated $148K and bringing the position to 18,658 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2636.

Nuveen first reported a position in INBX in Q2 2024 and has held it in 9 quarters since. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Nuveen held 18,658 shares of Inhibrx worth $1.77M as of Q2 2026.
  • Nuveen bought 1,481 Inhibrx shares in Q2 2026, an estimated $148K.
  • Inhibrx made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2636 holding.
  • Nuveen first reported a position in Inhibrx in Q2 2024 and has held it in 9 quarters since.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.